Bruker Corporation (NASDAQ:BRKR) – Leerink Swann increased their FY2017 earnings per share (EPS) estimates for shares of Bruker Corporation in a report issued on Thursday. Leerink Swann analyst P. Souda now expects that the medical research company will post earnings of $1.19 per share for the year, up from their previous estimate of $1.10. Leerink Swann also issued estimates for Bruker Corporation’s Q2 2018 earnings at $0.27 EPS, Q3 2018 earnings at $0.34 EPS and FY2018 earnings at $1.34 EPS.

Other equities research analysts also recently issued research reports about the stock. BidaskClub raised shares of Bruker Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Barclays PLC reaffirmed an “equal weight” rating and set a $30.00 price target (up previously from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating and set a $29.00 price target on shares of Bruker Corporation in a research note on Friday, July 14th. Citigroup Inc. lifted their price target on shares of Bruker Corporation from $29.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Finally, Bank of America Corporation raised shares of Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price target on the stock in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $28.58.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/08/leerink-swann-comments-on-bruker-corporations-fy2017-earnings-brkr.html.

Shares of Bruker Corporation (NASDAQ BRKR) opened at $32.77 on Monday. Bruker Corporation has a one year low of $21.03 and a one year high of $35.16. The stock has a market cap of $5,243.04, a price-to-earnings ratio of 28.30, a P/E/G ratio of 2.84 and a beta of 1.05. The company has a current ratio of 2.63, a quick ratio of 1.61 and a debt-to-equity ratio of 0.56.

Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.93%. The firm had revenue of $435.60 million for the quarter, compared to the consensus estimate of $415.45 million. During the same quarter in the previous year, the firm posted $0.32 EPS. The firm’s quarterly revenue was up 10.6% on a year-over-year basis.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Bruker Corporation by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock valued at $229,391,000 after buying an additional 277,111 shares during the period. Koch Industries Inc. boosted its holdings in shares of Bruker Corporation by 2,573.5% in the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after buying an additional 322,252 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Bruker Corporation by 4.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 524,525 shares of the medical research company’s stock valued at $12,238,000 after buying an additional 24,115 shares during the period. AJO LP acquired a new position in shares of Bruker Corporation in the 2nd quarter valued at about $46,075,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Bruker Corporation by 186.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock valued at $475,000 after buying an additional 10,723 shares during the period. 65.73% of the stock is owned by institutional investors and hedge funds.

In other news, VP Mark Munch sold 21,061 shares of Bruker Corporation stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Frank H. Laukien purchased 2,335 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was acquired at an average cost of $27.39 per share, with a total value of $63,955.65. Following the completion of the acquisition, the chief executive officer now directly owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. Insiders own 35.20% of the company’s stock.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker Corporation (NASDAQ:BRKR)

Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.